Injectable Fillers Facing the 1 March 2027 MDACS Listing Mandate

1. Key takeaways

This is the first medical device mandatory requirement in Hong Kong, China in recent years that is precise as to product category and precise as to date. In a letter dated 9 September 2026, the Office for Regulation of Private Healthcare Facilities of the Department of Health set out that all injectable and infusible products used in licensed private healthcare facilities must fall within one of 3 categories: a pharmaceutical product registered or exempt from registration under the Pharmacy and Poisons Regulations (Cap. 138A); a human organ or human tissue product meeting the Human Organ Transplant Ordinance (Cap. 465); or a medical device already listed on the Medical Device Administrative Control System (MDACS). The mandatory requirement for the third category takes effect on 1 March 2027, and the letter specifically names injectable dermal fillers and injectable mucosal fillers.

• The obligation is imposed on the point of use, but its commercial effect is felt by suppliers, because facilities will only buy products that satisfy it.
• The three categories are exhaustive, so a product that fits none of them has no lawful route into a licensed facility after the effective date.
• The device limb of the requirement starts later than the rest of the amended code, which creates a defined window for filing.
• Attribute determines outcome: the same filler may be presented as a cosmetic or as clinic stock, but the legal test is whether it is a medical device.
• Licence conditions give facility operators a direct incentive to stop purchasing unlisted products rather than to wait and see.

2. Legal basis

The requirement is set out in a circular from the Office for Regulation of Private Healthcare Facilities, and it operates through the licensing regime for private healthcare facilities and through the ordinances that govern pharmaceutical products and human tissue. The table below lists the instruments and provisions relied on in this article.

The structure of the requirement is worth noting. The circular does not create a new registration regime; it uses the existing three categories and requires every product in scope to sit inside one of them. For devices, that means the MDACS listing becomes the only route by which an injectable or infusible device can remain in use in a licensed facility once the device limb takes effect.

3. Expert insights

First, this is a use-side mandate, but the pressure travels upward to manufacturers. The document binds licensed private healthcare facilities, including private hospitals, day procedure centres and licensed clinics. Those facilities will nevertheless require suppliers to provide listed products in order to satisfy their own obligations. Unlisted fillers will be refused by facilities after 1 March 2027, which makes the requirement a substantive market access threshold rather than a technicality for the facility sector alone.

Second, the time account has to start now. The amended code of practice is planned for gazettal in the fourth quarter of 2026, with effect one month after gazettal for everything except the device provisions, and with the device requirement taking effect on 1 March 2027. Counting back from a 12-week review plus 2 weeks for acknowledgement, submission should take place no later than the fourth quarter of 2026 (practical estimate, with a buffer already allowed for supplementation). A project that starts in January 2027 will not finish before the effective date.

Third, attribute determination is the first hurdle. The same filler may be sold by a manufacturer as a cosmetic or as clinic stock. The test is whether the product is a medical device under the laws of Hong Kong, China. If it is a medical device and it is injected or infused in a licensed facility, it must be listed, and that conclusion does not depend on how the supplier markets it. Marketing language may affect how the product is perceived, but it does not change the legal classification.

Fourth, section 47 of Cap. 633 is the enforcement hook. A licensee is responsible for the operation of the facility, including compliance with the code of practice, and compliance with the code is a condition for the issue and renewal of a licence. That structure gives facilities a strong incentive to clear unlisted products proactively, and it explains why the practical pressure on suppliers arrives earlier than the statutory effective date suggests.

4. Practical recommendations

• Start attribute determination immediately. For fillers and for every injectable or infusible product, determine model by model whether the product is a pharmaceutical product, a human tissue product or a medical device.
• Schedule submissions against the fourth quarter of 2026. Compress appointment of the Local Responsible Person (LRP) and opening of an account on the Medical Device Information System (MDIS) and dossier preparation into October to December 2026.
• Give customers a listing status statement. Manufacturers should provide facility customers with the listing progress of each product in advance, so that they are not caught by a clearance list.
• Watch for gazettal of the code of practice. Once the fourth-quarter gazettal appears, check the final wording of the device chapter immediately and confirm that it matches the letter.

5. Verification checklist

• □ Attribute determination for injectable and infusible products is complete, model by model
• □ Whether each product is a medical device has been confirmed, together with its class
• □ A listing submission timetable has been counted back from 1 March 2027
• □ LRP appointment and MDIS account opening have been initiated
• □ A listing progress statement has been issued to facility customers
• □ Progress of the gazettal of the code of practice is being tracked, with published texts retained

Regulatory information verified to 29 October 2026. The legislation, guidance and effective dates described in this article are limited to what the official sources listed under Legal basis had published on that date; where an official document has since been updated, the most recent published version prevails.

How GRZAN can help. GRZAN provides medical device and IVD registration, quality system, authorised representative and local testing support for Hong Kong, China. Our team manages MDACS listing applications across all risk classes, prepares reference-approval dossiers, and supports post-market vigilance obligations. Business enquiries: info@grzanglobal.com